HONG KONG, July 18, 2011 /PRNewswire/ — Data from high-risk
patients requiring early discontinuation of dual antiplatelet
therapy (DAPT) due to nondeferrable, non-cardiac surgery show good
short- and long-term clinical and safety outcomes following
treatment with OrbusNeich’s Genous Stent, according to a study
published online on the journal
Minerva Cardioangiologica‘s website.
In the single-center study, patients treated with the Genous
endothelial progenitor cell (EPC) capture stent discontinued DAPT
between 21 and 30 days post-procedure and underwent non-cardiac
surgical intervention within 60 days of percutaneous coronary
intervention (PCI). Despite the shortened period of DAPT
administration, there were no cases of stent thrombosis (ST)
observed in patients treated with Genous. Additionally, no
cases of perioperative major adverse cardiac events (MACE) were
detected. After a mean follow-up of 15.4+/-10.3 months, two cases
of cardiac death were reported, with no ischemia-driven target
lesion revascularization (TLR) observed.
“Patients in need of revascularization and subsequent
non-cardiac surgery are a significant management challenge due to
their increased risk for major adverse cardiovascular events
related to stent thrombosis and intra-operative bleeding,” said
Paolo Scacciatella, M.D., of the Department of Cardiovascular and
Thoracic Diseases, S. Giovanni Battista University Hospital, Turin,
Italy, and lead author of the publication. “The results from this
study confirm the feasibility and safety of the Genous Stent in
patients requiring early discontinuation of DAPT as a result of
nondeferrable surgical intervention. Given the lack of stent
thrombosis over the long term in patients with high clinical and
angiographic risk, the Genous Stent represents an attractive
alternative to bare metal and drug eluting stents f
‘/>”/>
SOURCE